CorMedix (CRMD) director reports option exercises and 34,000-share sale

Rhea-AI Filing Summary

CorMedix Inc. director Janet Dillione reported exercising stock options and selling shares of the company’s common stock on 12/09/2025. She exercised options to buy 19,000 shares at $9.55 per share and another 15,000 shares at $5.63 per share, receiving a total of 34,000 shares.

On the same day, she sold 34,000 shares of CorMedix common stock at a weighted average price of $12.00 per share, with individual trades ranging from $12.00 to $12.02. After these transactions, she directly owned 48,473 shares of CorMedix common stock. The exercised options, originally granted in 2016 and 2020 and now fully vested, were reduced to zero following the transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dillione Janet

(Last) (First) (Middle)

C/O CORMEDIX INC.,

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M		19,000	A	$9.55	67,473	D
Common Stock	12/09/2025		M		15,000	A	$5.63	82,473	D
Common Stock	12/09/2025		S		34,000	D	$12(1)	48,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$9.55	12/09/2025		M			19,000	(2)	02/21/2026	Common Stock	19,000	$0	0	D
Stock Option (Right to Buy Common Stock)	$5.63	12/09/2025		M			15,000	(3)	02/25/2030	Common Stock	15,000	$0	0	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $12.00 to $12.02, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected

2. These options were granted on 02/21/2016. These options are fully vested.

3. These options were granted on 02/25/2020. These options are fully vested.

	/s/ Janet Dillione	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) report on 12/09/2025?

CorMedix reported that director Janet Dillione exercised options for a total of 34,000 shares of common stock and sold 34,000 shares on 12/09/2025.

How many CorMedix (CRMD) shares did the director sell and at what price?

The director sold 34,000 shares of CorMedix common stock at a weighted average price of $12.00 per share, with trade prices ranging from $12.00 to $12.02.

What stock options did the CorMedix (CRMD) director exercise?

She exercised a stock option for 19,000 shares at an exercise price of $9.55 per share and another option for 15,000 shares at $5.63 per share, both on 12/09/2025.

How many CorMedix (CRMD) shares does the director own after these transactions?

Following the reported option exercises and sale, the director directly owned 48,473 shares of CorMedix common stock.

What is the status of the CorMedix (CRMD) stock options mentioned in this Form 4?

The options for 19,000 shares granted on 02/21/2016 and 15,000 shares granted on 02/25/2020 were fully vested and, after being exercised on 12/09/2025, the remaining number of these derivative securities beneficially owned was 0.

Who is the reporting person in this CorMedix (CRMD) Form 4 and what is their role?

The reporting person is Janet Dillione, who is identified as a Director of CorMedix Inc.